Comparing Invasive Pulmonary Aspergillosis Mortality Between Liposomal Amphotericin B and Voriconazole in Patients With Hematological Malignancy or Hematopoietic Stem Cell Transplantation.
hematological malignancy
invasive pulmonary aspergillosis
liposomal amphotericin b
outcome
voriconazole
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
20
11
2022
entrez:
26
12
2022
pubmed:
27
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Objectives We evaluated liposomal amphotericin B versus voriconazole for the treatment of invasive pulmonary aspergillosis (IPA) in patients with hematological malignancy or hematopoietic stem cell transplantation (HSCT). Methods This retrospective cohort, single-center study included patients with compatible radiological diagnosis of IPA between 2016 and 2021. Results Forty-six patients with hematological malignancy or HSCT were diagnosed with IPA. Thirty-nine of them fulfilled the criteria for comparing liposomal amphotericin B (n=15) with voriconazole (n=24). Their median age was 48.5 years. Stem cell transplant recipients were 45.65%, and nearly half of the patients (47.83%) had acute myeloid leukemia. Twenty-six (56.52%) of the patients did not require oxygen therapy. The 12-week mortality was 13.33% (two out of 15) in patients who received liposomal amphotericin B compared to 25% (six out of 24) in patients who received voriconazole. There was no mortality judged to be related to IPA. Success or global clinical response was not different between the two drugs: 80% for liposomal amphotericin B versus 83.33% for voriconazole. However, the safety profile favored liposomal amphotericin B. Conclusion In this small cohort, there was an equipoise in the mortality and clinical and radiological outcomes obtained using liposomal amphotericin B or voriconazole for the treatment of IPA in hematological malignancy or HSCT.
Identifiants
pubmed: 36569688
doi: 10.7759/cureus.31762
pmc: PMC9771842
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e31762Informations de copyright
Copyright © 2022, Mahmoud et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Antimicrob Agents Chemother. 2010 Aug;54(8):3432-41
pubmed: 20439615
Cancer. 2009 Jan 15;115(2):355-62
pubmed: 19117035
Blood. 2010 Dec 9;116(24):5111-8
pubmed: 20826719
Int J Infect Dis. 2013 Feb;17(2):e101-9
pubmed: 23084969
Am J Respir Crit Care Med. 2006 Jul 1;174(1):102; author reply 102-3
pubmed: 16793999
Clin Infect Dis. 2008 Feb 1;46(3):327-60
pubmed: 18177225
Clin Infect Dis. 2008 Sep 1;47(5):674-83
pubmed: 18637757
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
BMC Infect Dis. 2019 Mar 21;19(1):274
pubmed: 30898090
Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5
pubmed: 9564455
Clin Infect Dis. 2004 Sep 1;39(5):743-6
pubmed: 15356792
Mycopathologia. 2001;150(3):101-15
pubmed: 11469757
J Hosp Infect. 2020 Mar;104(3):358-364
pubmed: 31585141
Clin Infect Dis. 2007 May 15;44(10):1289-97
pubmed: 17443465
Am J Hematol. 2001 Dec;68(4):231-6
pubmed: 11754411
Drugs. 2016 Mar;76(4):485-500
pubmed: 26818726
Drugs. 2013 Jun;73(9):919-34
pubmed: 23729001
Clin Infect Dis. 2018 Aug 16;67(5):727-735
pubmed: 29718296
J Infect Public Health. 2020 Dec;13(12):2080-2086
pubmed: 31248814
N Engl J Med. 2002 Aug 8;347(6):408-15
pubmed: 12167683
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60
pubmed: 27365388
Clin Infect Dis. 2010 Dec 1;51(11):1273-80
pubmed: 21034199
Clin Infect Dis. 2000 Nov;31(5):1155-63
pubmed: 11073745
Infect Drug Resist. 2017 Feb 02;10:35-41
pubmed: 28203095
Ann Intern Med. 2015 Jan 20;162(2):81-9
pubmed: 25599346
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
PLoS One. 2015 Nov 10;10(11):e0140930
pubmed: 26554923